Department of Gene Therapy and Regenerative Medicine (GTRM)

Scientific rational research program

It is widely anticipated that improved gene therapy approaches will yield new treatments and cures for hereditary, acquired and complex diseases. Convincing evidence continues to emerge from clinical trials that gene therapy is yielding therapeutic effects in patients suffering from a wide range of diseases. It is therefore essential to continue to invest in gene and cell therapy to address some of the outstanding questions and overcome the remaining challenges.

Research vision and objectives

Applied translational research:

  • To develop and validate gene and cell therapy for major health- and life-threatening diseases.
  • To understand the molecular, cellular and immune mechanisms that influence the outcome of different gene/cell therapy approaches.
  • To conduct translational gene therapy studies in large animal models in anticipation of moving forward to the clinic and initiate phase I clinical trials.

Hypothesis-driven fundamental research:

  • To unravel the molecular mechanisms and pathways underlying various (patho)physiologic processes important in human health and disease.

Technology development:

  • To consolidate a broad state of the art technology platform based on the latest viral vectors (retroviral, lentiviral, AAV), non-viral vectors (PB and SB transposons), genome engineering systems (designer nucleases -TALEN) and stem cell technologies (iPS).

Priority programs

The main focus of our current research program in molecular medicine is to apply this conceptual framework in the context of genetic disorders, in particular hemophilia A & B , Duchenne muscular dystrophy and myotonic dystrophy. In addition, some research activities relate to cancer in association with the VUB Oncology Research Center


Prof. Dr. Thierry VandenDriessche - Research group Director

Prof. Dr. Marinee Chuah - Research group Co-Director

Dr. Janka Matrai (PhD) - Post-doctoral fellow

Dr. Melvin Rincon (MD) - PhD student

Dr. Kshitiz Singh (MD) - PhD student

Mariana Loperfido (MSc) - PhD student

Mario Di Matteo (MSc) - PhD student

Sumitava Dastidar (MSc)- PhD student

Nisha Nair (MSc)- PhD student

Shilpita Sarcar (MSc)- PhD student

Ermira Samara-Kuko (MSc)- Research assistant

Brenda Amondi - MSc student

Jessica Willems - MSc student

Omid Ghandeharian - MSc student

Hui Wang - PhD student (pending)

Selected publications

In chronological order - Scientific output consists of about 100 publications with nearly 3000 citations. Selected publications are shown (IF >10 papers are indicated with *).

  • *VandenDriessche et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc. Natl. Acad. Sci. USA 18 (96): 10379-10384 (1999).
  • *Carmeliet et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 7(5):575-83 (2001).
  • *VandenDriessche, et al. Lentiviral vectors containing the HIV-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100 (3): 813-822 (2002).
  • *Chuah et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 101(5):1734-1743 (2003).
  • *Yamada et al. Nanoparticles for the delivery of genes and drug into hepatocytes. Nat. Biotech. 21(8):885-890 (2003).
  • *De Meyer et al; Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood 107(12):4728-36 (2006).
  • *Aragones et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat. Genet., 40(2):170-80 (2008).
  • *Mates, Chuah et al. Molecular Evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat. Genet., 1(6):753-61 (2009).
  • *Bossuyt et al. Atonal homolog 1 is a tumor suppressor gene. Plos Biol.7(2):e39 (2009).
  • *Matsui et al. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells and IL-10. Blood, 114(3):677-85 (2009).
  • *Swinnen et al. The absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation, 120(16):1585- 97 (2009).
  • *VandenDriessche et al. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood, 114(8):1461-8 (2009).
  • *Schneider et al. Challenges with Advanced Therapy Medicinal Products and how to meet them: The European Committee for Advanced Therapies (CAT). Nat. Rev. Drug Disc.,9(3): 195-201 (2010).
  • *Dubois et al. Differential effects of progenitor cell populations on myocardial neovascularization and left ventricular remodeling after myocardial infarction. J. Am. Coll. Cardiol., 55(20):2232-43 (2010).
  • *Ward et al. Correction of murine hemophilia A using enhanced human factor VIII cDNAs encoding various B-domain variants. Blood, 117(3):798-807 (2010).
  • Belay et al. Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: a nonviral paradigm for coaxed differentiation. Stem Cells. 28(10):1760-71 (2010).
  • *Matrai et al. Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces transgene-specific immune tolerance with low genotoxic risk. Hepatology, 53(5):1696-1707 (2011).
  • Quattrocelli et al. Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs. J. Pathol. 223(5):593-603 (2011).


Prof. Dr. Thierry VandenDriessche

Prof. Dr. Marinee K.L. Chuah

Free University of Brussels (VUB)

Faculty of Medicine & Pharmacy

Department of Gene Therapy & Regenerative Medicine

Building D - 3rd floor

Laarbeeklaan 103

B-1090 Brussels (Jette)

Tel: +32-477-529653



Back to top

Research Cluster Reproduction, Genetics and Regenerative Medicine • ©2015 •
VUB • Faculty of Medicine & Pharmacy • Laarbeeklaan 103 • B-1090 Brussel, Belgium
Tel: +32 (0)2 477 46 35 •
Page generated in 0.0003 seconds.